share_log

Eli Lilly and Co | 10-Q: Q3 2024 Earnings Report

Eli Lilly and Co | 10-Q: Q3 2024 Earnings Report

禮來 | 10-Q：2024財年三季報
美股SEC公告 ·  2024/10/30 23:57

Moomoo AI 已提取核心訊息

Eli Lilly reported robust Q3 2024 financial results with revenue increasing 20% to $11.4 billion, driven by strong performance of Mounjaro and Zepbound. Net income reached $970.3 million or $1.07 per share, compared to a loss in Q3 2023. U.S. revenue grew 46% to $7.8 billion, while revenue outside U.S. declined 12% to $3.6 billion, primarily due to the sale of the olanzapine portfolio.Mounjaro revenue in the U.S. surged to $2.38 billion, while newly launched Zepbound contributed $1.26 billion. However, sales were impacted by inventory decreases in the wholesaler channel following higher levels in Q2. Verzenio revenue increased 32% to $1.37 billion on strong demand, while Trulicity revenue declined 22% to $1.30 billion due to competitive pressures.The company's gross margin improved to 81.0% from 80.4% year-over-year, benefiting from favorable product mix and higher realized prices. Research and development expenses increased 13% to $2.73 billion, while marketing and administrative expenses rose 16% to $2.10 billion. The company continues to expand manufacturing capacity for incretin medicines to meet growing demand.
Eli Lilly reported robust Q3 2024 financial results with revenue increasing 20% to $11.4 billion, driven by strong performance of Mounjaro and Zepbound. Net income reached $970.3 million or $1.07 per share, compared to a loss in Q3 2023. U.S. revenue grew 46% to $7.8 billion, while revenue outside U.S. declined 12% to $3.6 billion, primarily due to the sale of the olanzapine portfolio.Mounjaro revenue in the U.S. surged to $2.38 billion, while newly launched Zepbound contributed $1.26 billion. However, sales were impacted by inventory decreases in the wholesaler channel following higher levels in Q2. Verzenio revenue increased 32% to $1.37 billion on strong demand, while Trulicity revenue declined 22% to $1.30 billion due to competitive pressures.The company's gross margin improved to 81.0% from 80.4% year-over-year, benefiting from favorable product mix and higher realized prices. Research and development expenses increased 13% to $2.73 billion, while marketing and administrative expenses rose 16% to $2.10 billion. The company continues to expand manufacturing capacity for incretin medicines to meet growing demand.
禮來公司公佈了2024年第三季度的財務業績，營業收入增長了20%，達到了114億美元，主要得益於Mounjaro和Zepbound的強勁表現。凈利潤達到97030萬美元，或每股1.07美元，而2023年第三季度則出現了虧損。美國的營業收入增長了46%，達到了78億美元，然而美國以外的營業收入下降了12%，降至36億美元，主要是由於奧氮平產品組合的銷售。Mounjaro在美國的營業收入猛增至23.8億美元，而新推出的Zepbound貢獻了12.6億美元。然而，由於批發渠道在第二季度的庫存水平較高，銷售受到影響。Verzenio的營業收入增長了32%，達到了13.7億美元，強勁的需求促進了這一增長...展開全部
禮來公司公佈了2024年第三季度的財務業績，營業收入增長了20%，達到了114億美元，主要得益於Mounjaro和Zepbound的強勁表現。凈利潤達到97030萬美元，或每股1.07美元，而2023年第三季度則出現了虧損。美國的營業收入增長了46%，達到了78億美元，然而美國以外的營業收入下降了12%，降至36億美元，主要是由於奧氮平產品組合的銷售。Mounjaro在美國的營業收入猛增至23.8億美元，而新推出的Zepbound貢獻了12.6億美元。然而，由於批發渠道在第二季度的庫存水平較高，銷售受到影響。Verzenio的營業收入增長了32%，達到了13.7億美元，強勁的需求促進了這一增長，而Trulicity的營業收入下降了22%，降至13億美元，主要受到競爭壓力的影響。公司的毛利率從去年的80.4%提高到81.0%，得益於有利的產品組合和更高的實際價格。研發費用增加了13%，達到了27.3億美元，而市場營銷和管理費用上升了16%，達到了21億美元。公司繼續擴大用於增效藥物的製造能力，以滿足日益增長的需求。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    施貴寶
    BMY
    -- 60.020
    默沙東
    MRK
    -- 89.230
    賽諾菲安萬特
    SNY
    -- 55.820
    阿斯利康
    AZN
    -- 73.790
    艾伯維公司
    ABBV
    -- 205.290
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股財報季火熱：驚喜盈利能否延續漲勢？
    1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點